The award will fund development of a rapid, sensitive, and specific diagnostic system for the culture-independent identification and determination of antimicrobial susceptibility of bacterial pathogens from whole blood.
Talis is developing a high-performance diagnostic platform to enable physician offices and clinics to run reference lab quality diagnostic tests for infectious diseases at the point-of-care.
Point-of-care diagnostic platforms that can measure the drug susceptibility of a pathogen directly from clinical samples, eliminating lengthy procedures that require microbial growth can help in the fight against antibiotic resistant organisms.
The Talis system leverages proprietary isothermal amplification chemistries, innovative engineering and data science tools. The rapid, digital quantification capability of the company's proprietary SlipChip technology of parallel processing of thousands of nanoliter volume chambers will enable pathogen identification and susceptibility to antibiotics in less than two hours.
Talis is developing a new class of diagnostic systems to enable rapid, point of care testing across a wide range of healthcare settings. From the doctor's office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary